Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accustem Sciences Inc.ACUT · Entity 8467 | Director | December 01, 2021 | May 27, 2022 |
| OKYO Pharma LtdOKYO · Entity 6916 | Director | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accustem Sciences Inc.
Report date December 01, 2021 · Filed May 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 413 |
Reported balance
Holding disclosure · report date 2021-12-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 413 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2031-08-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-12-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2032-01-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-12-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
OKYO Pharma Ltd
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2036-06-08 | Direct | 135,502 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 6,500 · Balance 135,502 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 10, 2026 21:00 UTC | OKYO Pharma Ltd OKYO · Entity 6916 | GrantOption · Derivative | 6,500 | $1.85 Strike: $1.85 | $12,025.00 |
DisclosureSEC source: 0001493152-26-028132 · ownership.xml · derivative · entry 1 Simon Willy Jules · CIK 0001325410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,502 Underlying: Common Shares · 6,500 shares Expires 2036-06-08 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.